Clinical Trial Update: PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a phase 1/2 study of PEP-CMV in combination with nivolumab for newly diagnosed and recurrent diffuse midline glioma/high-gr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Midline Glioma
• Diffuse Midline High-grade Glioma
• Ependymoma
• Medulloblastoma

Drugs mentioned

• PEP-CMV
• nivolumab (nivolumab)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Diffuse Midline Glioma, Diffuse Midline High-grade Glioma | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING